Filing summary
Issuer and period: The supplied filing is KemPharm, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 11, 2021. It is not a Zevra Therapeutics filing; investors should confirm the issuer and ticker before relying on this summary. The filing reports annual results, not a standalone 2020 fourth-quarter statement.
Business context and key financial metrics
KemPharm was a specialty pharmaceutical company developing proprietary prodrugs. Its pipeline included AZSTARYS and KP484 for ADHD, KP879 for stimulant use disorder, and preclinical KP1077 for idiopathic hypersomnia. FDA-approved APADAZ was partnered with KVK-Tech. Commercial revenue was primarily from license and consulting arrangements, not product sales.
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $13.3 million | $12.8 million |
| Operating expenses | $18.9 million | $33.2 million |
| Operating loss | $5.6 million | $20.3 million |
| Net loss | $12.8 million | $24.5 million |
| Net loss per share, basic and diluted | $3.21 | $13.23 |
| Cash used in operating activities | $1.9 million | $23.7 million |
| Cash and cash equivalents at year-end | $4.2 million | $3.2 million |
| Total assets at year-end | $11.2 million | $10.5 million |
| Total liabilities at year-end | $77.6 million | $85.0 million |
| Convertible notes, net, at year-end | $67.7 million | $77.3 million |
| Accumulated deficit at year-end | $258.5 million | $245.7 million |
The filing does not provide a conventional gross-margin measure. No dividends were paid, and management said it expected to retain future earnings, if any, to fund operations.
Changes versus 2019
- Revenue rose $0.4 million. Consulting revenue increased by $5.3 million, mainly from the Corium agreement, while licensing and milestone revenue fell $5.0 million as the prior year included a $10.0 million upfront license payment and 2020 included a $5.0 million NDA-acceptance milestone.
- Research and development expense declined $10.6 million to $8.8 million, primarily reflecting lower net third-party development costs. General and administrative expense declined $2.9 million to $7.9 million.
- Net loss improved by $11.8 million, chiefly because of lower operating expenses. This was partly offset by a year-over-year swing in derivative and warrant fair-value results—from $2.0 million of income in 2019 to $0.2 million of expense in 2020—and higher net interest and other expense.
- Operating cash use fell substantially, to $1.9 million from $23.7 million. Year-end cash remained limited at $4.2 million, and stockholders’ deficit was $66.4 million.
Outlook, material events, and risks
- AZSTARYS: The FDA approved the ADHD treatment on March 2, 2021, after year-end. Corium was expected to lead U.S. commercialization, with launch anticipated as early as the second half of 2021. The approval milestone was earned under the Commave license, but the filing does not state a clear amount for that approval payment.
- Pipeline: Management expected to initiate the KP879 clinical program in 2021 and hold a pre-IND meeting for KP1077 in 2021. KP484’s next pivotal-trial timing was subject to Commave’s direction.
- Funding and debt after year-end: A January 2021 public offering generated $52.4 million gross, and warrant inducement transactions generated a further $44.0 million gross. The company paid $8.0 million in February 2021 to repay and terminate the remaining Deerfield facility debt. These are subsequent events, not 2020 operating results. Management estimated that available funds after these transactions would support operations through at least Q1 2024; the estimate depended on assumptions and excluded projected revenue.
- Partner economics: Commave’s agreement included up to $63.0 million in regulatory milestones, up to $420.0 million in U.S. sales milestones, and tiered royalties. Aquestive was entitled to 10% of value generated by SDX-containing products. APADAZ’s KVK arrangement included sales milestones and a 30%–50% share of U.S. net profits, subject to agreement terms and commercial performance.
- Liquidity and profitability: The company had recurring losses and negative operating cash flows, and warned it might need additional capital. The audited statements were prepared on a going-concern basis; management said the post-year-end financing and debt actions alleviated the concern that year-end cash alone was insufficient for a year of operations.
- Key risks: Commercial adoption and partner execution; competition and reimbursement; clinical and regulatory uncertainty; controlled-substance regulation and production quotas; reliance on third-party manufacturers, including sole-source supply; intellectual-property protection; COVID-19-related disruption; and potential dilution from equity, preferred stock, and warrants.
- Other notable items: The company received a $0.8 million Paycheck Protection Program loan and was awaiting a forgiveness decision; it said substantially all was expected to be forgiven but gave no assurance. A $0.8 million severance charge followed the departure of the chief business officer. Management reported effective disclosure controls and internal control over financial reporting; the external auditor did not attest to ICFR effectiveness.
Important facts for investors to verify
- Confirm this filing belongs to the intended issuer: it identifies KemPharm, Inc. (ticker KMPH), not Zevra Therapeutics.
- Check the amount, timing, and conditions of the AZSTARYS approval milestone and any subsequent royalties, and verify launch and sales performance.
- Review post-year-end cash, financing costs, outstanding warrants and preferred-stock conversions, and the fully diluted share count; the filing reports 28,376,321 common shares outstanding as of March 10, 2021.
- Verify the Q1 2024 cash-runway estimate against actual spending, consulting receipts, and milestone or royalty collections.
- Check PPP loan forgiveness status and any remaining repayment obligation.
- Assess APADAZ uptake and the economics and progress of KVK’s regional launch, as well as development and commercialization decisions by Commave.